Valneva Se ADR (VALN)

Apr 18, 2025, 4:00 AM EDT - 5 days ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Apr 16, 2025, 11:45 AM EDT - 7 days ago

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Apr 14, 2025, 2:28 PM EDT - 9 days ago

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Apr 14, 2025, 11:45 AM EDT - 9 days ago

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Apr 9, 2025, 1:00 AM EDT - 14 days ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Apr 7, 2025, 9:33 AM EDT - 16 days ago

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Apr 3, 2025, 11:45 AM EDT - 20 days ago

Valneva SE Shareholding Declaration - March 2025

Apr 1, 2025, 11:45 AM EDT - 22 days ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Mar 31, 2025, 1:00 AM EDT - 23 days ago

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Mar 26, 2025, 1:00 PM EDT - 4 weeks ago

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Mar 25, 2025, 2:00 AM EDT - 4 weeks ago

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Mar 24, 2025, 2:00 AM EDT - 4 weeks ago

Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Mar 20, 2025, 8:00 PM EDT - 4 weeks ago

Valneva SE (VALN) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation

Mar 20, 2025, 2:00 AM EDT - 4 weeks ago

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Mar 19, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out

Mar 18, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation

Mar 17, 2025, 10:00 AM EDT - 5 weeks ago

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 16, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation

Mar 14, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect

Mar 13, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation

Mar 12, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation

Mar 11, 2025, 10:00 AM EDT - 6 weeks ago

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 9, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect

Mar 7, 2025, 10:00 AM EST - 6 weeks ago

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 6, 2025, 10:00 AM EST - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation.

Mar 5, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Investors to Inquire about Securities Investigation

Mar 4, 2025, 1:45 PM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out

Mar 3, 2025, 1:00 AM EST - 7 weeks ago

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Feb 28, 2025, 11:45 AM EST - 7 weeks ago

Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

Feb 18, 2025, 1:00 AM EST - 2 months ago

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Feb 5, 2025, 1:00 AM EST - 2 months ago

Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ®

Jan 30, 2025, 11:45 AM EST - 2 months ago

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

Jan 23, 2025, 3:48 PM EST - 3 months ago

Valneva Is A 'Buy' As A First-Mover In Chikungunya

Jan 22, 2025, 11:45 AM EST - 3 months ago

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

Jan 21, 2025, 10:44 AM EST - 3 months ago

Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot

Jan 20, 2025, 11:45 AM EST - 3 months ago

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Jan 6, 2025, 11:45 AM EST - 3 months ago

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Dec 19, 2024, 2:00 AM EST - 4 months ago

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

Dec 4, 2024, 1:00 AM EST - 5 months ago

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Dec 3, 2024, 1:00 AM EST - 5 months ago

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Nov 26, 2024, 11:45 AM EST - 5 months ago

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

Nov 15, 2024, 11:21 AM EST - 5 months ago

European And US Vaccine Stocks Are Under Pressure - Here's WHy

AZN BNTX GSK INO MRK SNY

Nov 13, 2024, 11:45 AM EST - 5 months ago

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2